REPORT ID 432

United States Sexually Transmitted Diseases (STDs) Drug Market Report 2017

Publish Date
01-Dec-17
Pages
99
Format
Electronic (PDF)

In this report, the United States Sexually Transmitted Diseases (STDs) Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Sexually Transmitted Diseases (STDs) Drug in these regions, from 2012 to 2022 (forecast).

United States Sexually Transmitted Diseases (STDs) Drug market competition by top manufacturers/players, with Sexually Transmitted Diseases (STDs) Drug sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer
    Hoffmann La Roche
    Bayer Healthcare
    Eli Lilly
    Johnson & Johnson
    Bristol-Myers Squibb
    AbbVie, Inc.
    Gilead Sciences
    GlaxoSmithKline Plc
    Merck & Co., Inc.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    by Disease Type
        Chlamydia
        Gonorrhea
        Syphilis
        Genital herpes
        HPV
        HIV / AIDS
    by Therapy Class
        Antibiotics
        Antiviral / Antiretrovirals
        Vaccines
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital Pharmacies
    Retail Pharmacies
    Online Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Sexually Transmitted Diseases (STDs) Drug Market Report 2017
1 Sexually Transmitted Diseases (STDs) Drug Overview
    1.1 Product Overview and Scope of Sexually Transmitted Diseases (STDs) Drug
    1.2 Classification of Sexually Transmitted Diseases (STDs) Drug by Product Category
        1.2.1 United States Sexually Transmitted Diseases (STDs) Drug Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Sexually Transmitted Diseases (STDs) Drug Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Chlamydia
        1.2.4 Gonorrhea
        1.2.5 Syphilis
        1.2.6 Genital herpes
        1.2.7 HPV
        1.2.8 HIV / AIDS
    1.3 United States Sexually Transmitted Diseases (STDs) Drug Market by Application/End Users
        1.3.1 United States Sexually Transmitted Diseases (STDs) Drug Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospital Pharmacies
        1.3.3 Retail Pharmacies
        1.3.4 Online Pharmacies
    1.4 United States Sexually Transmitted Diseases (STDs) Drug Market by Region
        1.4.1 United States Sexually Transmitted Diseases (STDs) Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Sexually Transmitted Diseases (STDs) Drug Status and Prospect (2012-2022)
        1.4.3 Southwest Sexually Transmitted Diseases (STDs) Drug Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Sexually Transmitted Diseases (STDs) Drug Status and Prospect (2012-2022)
        1.4.5 New England Sexually Transmitted Diseases (STDs) Drug Status and Prospect (2012-2022)
        1.4.6 The South Sexually Transmitted Diseases (STDs) Drug Status and Prospect (2012-2022)
        1.4.7 The Midwest Sexually Transmitted Diseases (STDs) Drug Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Sexually Transmitted Diseases (STDs) Drug (2012-2022)
        1.5.1 United States Sexually Transmitted Diseases (STDs) Drug Sales and Growth Rate (2012-2022)
        1.5.2 United States Sexually Transmitted Diseases (STDs) Drug Revenue and Growth Rate (2012-2022)

2 United States Sexually Transmitted Diseases (STDs) Drug Market Competition by Players/Suppliers
    2.1 United States Sexually Transmitted Diseases (STDs) Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Sexually Transmitted Diseases (STDs) Drug Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Sexually Transmitted Diseases (STDs) Drug Average Price by Players/Suppliers (2012-2017)
    2.4 United States Sexually Transmitted Diseases (STDs) Drug Market Competitive Situation and Trends
        2.4.1 United States Sexually Transmitted Diseases (STDs) Drug Market Concentration Rate
        2.4.2 United States Sexually Transmitted Diseases (STDs) Drug Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Sexually Transmitted Diseases (STDs) Drug Manufacturing Base Distribution, Sales Area, Product Type

3 United States Sexually Transmitted Diseases (STDs) Drug Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Sexually Transmitted Diseases (STDs) Drug Sales and Market Share by Region (2012-2017)
    3.2 United States Sexually Transmitted Diseases (STDs) Drug Revenue and Market Share by Region (2012-2017)
    3.3 United States Sexually Transmitted Diseases (STDs) Drug Price by Region (2012-2017)

4 United States Sexually Transmitted Diseases (STDs) Drug Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Sexually Transmitted Diseases (STDs) Drug Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Sexually Transmitted Diseases (STDs) Drug Revenue and Market Share by Type (2012-2017)
    4.3 United States Sexually Transmitted Diseases (STDs) Drug Price by Type (2012-2017)
    4.4 United States Sexually Transmitted Diseases (STDs) Drug Sales Growth Rate by Type (2012-2017)

5 United States Sexually Transmitted Diseases (STDs) Drug Sales (Volume) by Application (2012-2017)
    5.1 United States Sexually Transmitted Diseases (STDs) Drug Sales and Market Share by Application (2012-2017)
    5.2 United States Sexually Transmitted Diseases (STDs) Drug Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Sexually Transmitted Diseases (STDs) Drug Players/Suppliers Profiles and Sales Data
    6.1 Pfizer
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Sexually Transmitted Diseases (STDs) Drug Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Pfizer Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Hoffmann La Roche
        6.2.2 Sexually Transmitted Diseases (STDs) Drug Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Bayer Healthcare
        6.3.2 Sexually Transmitted Diseases (STDs) Drug Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Eli Lilly
        6.4.2 Sexually Transmitted Diseases (STDs) Drug Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Johnson & Johnson
        6.5.2 Sexually Transmitted Diseases (STDs) Drug Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Bristol-Myers Squibb
        6.6.2 Sexually Transmitted Diseases (STDs) Drug Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 AbbVie, Inc.
        6.7.2 Sexually Transmitted Diseases (STDs) Drug Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Gilead Sciences
        6.8.2 Sexually Transmitted Diseases (STDs) Drug Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 GlaxoSmithKline Plc
        6.9.2 Sexually Transmitted Diseases (STDs) Drug Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Merck & Co., Inc.
        6.10.2 Sexually Transmitted Diseases (STDs) Drug Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview

7 Sexually Transmitted Diseases (STDs) Drug Manufacturing Cost Analysis
    7.1 Sexually Transmitted Diseases (STDs) Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Sexually Transmitted Diseases (STDs) Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Sexually Transmitted Diseases (STDs) Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Sexually Transmitted Diseases (STDs) Drug Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Sexually Transmitted Diseases (STDs) Drug Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Sexually Transmitted Diseases (STDs) Drug Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Sexually Transmitted Diseases (STDs) Drug Sales Volume Forecast by Type (2017-2022)
    11.3 United States Sexually Transmitted Diseases (STDs) Drug Sales Volume Forecast by Application (2017-2022)
    11.4 United States Sexually Transmitted Diseases (STDs) Drug Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer